RxDoctor Payments Data

George Boctor, MD

Internal Medicine · Fort Lauderdale, FLNPI 1194925560

Payments from drug & device makers

$1,635in general payments, 2019–2025

Across 81 payments — averaging $20.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$262
  • GSK$229
  • Johnson & Johnson$228
  • Pfizer$170
  • Amgen$167
  • AstraZeneca$135
  • plus $445 from 10 others

What the payments were for

  • Food & beverage$1,635100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,635 in reported general payments places this provider in the 75th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$77,918
Medicare patients
183
Services billed
827

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban99$107,014
Trelegy ElliptaFluticasone/Umeclidin/Vilanter81$61,527
XareltoRivaroxaban39$50,576
EntrestoSacubitril/Valsartan57$50,087
JanuviaSitagliptin Phosphate37$48,651
TradjentaLinagliptin19$23,479
OzempicSemaglutide16$23,205
Breo ElliptaFluticasone/Vilanterol28$16,966
SymbicortBudesonide/Formoterol Fumarate35$13,396
Atorvastatin Calcium904$7,792
Adacel TdapDiph,pertuss(Acell),tet Vac/Pf92$6,477
SynthroidLevothyroxine Sodium46$4,236
Omeprazole252$4,163
Rosuvastatin Calcium229$3,547
Fenofibrate22$3,417

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$170$107,01499 claims
GSKTrelegy Ellipta, Breo Ellipta$229$78,493109 claims
Johnson & JohnsonXarelto$228$50,57639 claims
NovartisEntresto$262$50,08757 claims
Boehringer IngelheimTradjenta$64$23,47919 claims
Novo NordiskOzempic$76$23,20516 claims
AstraZenecaSymbicort$135$13,39635 claims
AbbVieSynthroid$29$4,23646 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Fort Lauderdale

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →